Evaluation of 3-V Bioscience-2640, a FASN Inhibitor, to Reduce de Novo Lipogenesis in Subjects With Characteristics of the Metabolic Syndrome
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs TVB 2640 (Primary)
- Indications Metabolic syndrome; Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- 16 Oct 2017 According to a 3-V Biosciences media release, data will be presented at the at the upcoming AASLD meeting at The Liver Meeting 2017.
- 14 Feb 2017 Planned End Date changed from 1 Aug 2018 to 31 Jan 2018.
- 14 Feb 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Nov 2017.